Impact casting a wide synthetic lethality net

Impact aims to build synthetic lethality pipeline of validated DNA damage repair, novel targets

After laying the foundation with its PARP inhibitor, Impact plans to build a comprehensive synthetic lethality pipeline across known DNA damage repair targets and new ones outside of DDR to address a wider range of cancer mutations than other synthetic lethality companies.

The principle of synthetic lethality is that while cancer cells can tolerate or even benefit from losing one regulator of DNA damage repair, simultaneous inhibition of a second DDR protein causes overwhelming genetic damage that triggers cell death.

PARP inhibitors are the prime example, producing

Read the full 865 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE